source
- Zealand Pharma sells its rights to Takeda's rusfertide for $100 million ahead of FDA decisionZealand Pharma has agreed to sell its economic interest in rusfertide, a peptide drug being developed by Takeda and Protagonist Therapeutics, for $100 million. The transaction comes as the FDA rev…
- STAT+ probes Commure’s AI-driven health-care platform and Medicare’s new incentives for AI medical devicesThe STAT Health Tech newsletter edition dated Aug 13, 2026 features an investigative piece on Commure, a General Catalyst-backed firm that claims to automate health-care operations using artificial…